Literature DB >> 14688276

Translational control of tumor necrosis factor-related apoptosis-inducing ligand death receptor expression in melanoma cells.

Xi Yi Zhang1, Xu Dong Zhang, Jodie M Borrow, Tam Nguyen, Peter Hersey.   

Abstract

In the present study, it was found that tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-R2 protein expression did not correlate with mRNA expression in melanoma cell lines. In particular, early passage primary cultures from patients had low TRAIL-R2 protein expression compared with later passage cultures although TRAIL-R2 mRNA expression was similar in early and late passages. Similarly, cell lines made resistant to TRAIL by cultures in TRAIL had low TRAIL-R2 protein expression but normal levels of mRNA for TRAIL-R2. Expression from a luciferase reporter gene construct with the 3'-untranslated region (UTR) (but not the 5'-UTR) of TRAIL-R2 was suppressed when transfected into the TRAIL-selected (resistant) melanoma lines compared with that seen in the parental (sensitive) lines. Similar results were seen in early passage (resistant) cultures compared with late passage (sensitive) primary melanoma cultures. RNA gel shift assays demonstrated protein(s) binding to the 3'-UTR of TRAIL-R2 mRNA that were more evident in TRAIL-resistant cultures with low TRAIL-R2 protein expression. A 23-base fragment of the 3'-UTR inhibited binding of the proteins to the 3'-UTR, and a probe using this fragment bound to proteins in TRAIL-selected melanoma lines and early passage isolates of melanoma. Binding of the 3'-UTR probe to the cytosolic protein(s) was induced by exposure to TRAIL and was lost from the TRAIL selected lines 2-3 days after withdrawal of TRAIL from the cultures. These results are consistent with post-transcriptional regulation of TRAIL-R2 expression by cytosolic proteins induced by TRAIL that bind to the 3'-UTR region of TRAIL-R2 mRNA.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14688276     DOI: 10.1074/jbc.M308211200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  7 in total

1.  TRAIL-induced apoptosis is enhanced by heat shock protein 70 expression.

Authors:  N J Clemons; R L Anderson
Journal:  Cell Stress Chaperones       Date:  2006       Impact factor: 3.667

Review 2.  Immune surveillance in melanoma: From immune attack to melanoma escape and even counterattack.

Authors:  Fade Mahmoud; Bradley Shields; Issam Makhoul; Nathan Avaritt; Henry K Wong; Laura F Hutchins; Sara Shalin; Alan J Tackett
Journal:  Cancer Biol Ther       Date:  2017-05-17       Impact factor: 4.742

3.  Indomethacin sensitizes TRAIL-resistant melanoma cells to TRAIL-induced apoptosis through ROS-mediated upregulation of death receptor 5 and downregulation of survivin.

Authors:  Anfernee Kai-Wing Tse; Hui-Hui Cao; Chi-Yan Cheng; Hiu-Yee Kwan; Hua Yu; Wang-Fun Fong; Zhi-Ling Yu
Journal:  J Invest Dermatol       Date:  2013-11-08       Impact factor: 8.551

4.  sTRAIL levels and TRAIL gene polymorphisms in Chinese patients with fatty liver disease.

Authors:  Xiaohua Yan; Liyun Xu; Jianni Qi; Xiaohong Liang; Chunhong Ma; Chun Guo; Lining Zhang; Wensheng Sun; Jiyun Zhang; Xiaoyi Wei; Lifen Gao
Journal:  Immunogenetics       Date:  2009-07-23       Impact factor: 2.846

5.  Proteasome inhibitor PS-341 (VELCADE) induces stabilization of the TRAIL receptor DR5 mRNA through the 3'-untranslated region.

Authors:  Karthikeyan Kandasamy; Andrew S Kraft
Journal:  Mol Cancer Ther       Date:  2008-05       Impact factor: 6.261

6.  Drug-induced caspase 8 upregulation sensitises cisplatin-resistant ovarian carcinoma cells to rhTRAIL-induced apoptosis.

Authors:  E W Duiker; A Meijer; A R M van der Bilt; G J Meersma; N Kooi; A G J van der Zee; E G de Vries; S de Jong
Journal:  Br J Cancer       Date:  2011-04-12       Impact factor: 7.640

7.  Splicing reprogramming of TRAIL/DISC-components sensitizes lung cancer cells to TRAIL-mediated apoptosis.

Authors:  Oliver H Voss; Daniel Arango; Justin C Tossey; Miguel A Villalona Calero; Andrea I Doseff
Journal:  Cell Death Dis       Date:  2021-03-17       Impact factor: 8.469

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.